Abstract: Methods, systems and programs for denoising a signal using an undecimated discrete wavelet transformation are provided. The methods use signal location windows. The signal location windows may be used before or after thresholding. When signal location windows are used after thresholding coefficients within the signal location windows may be restored to their original values. When signal location windows are used before thresholding, coefficients within the signal location windows may be unchanged by the thresholding. The signal location windows may be used only on a subset of decomposition levels that are thresholded. The signal location windows may be used on both the Detail components and the highest decomposition level for thresholding of the Approximation component.

Abstract: Systems and methods herein provide for a tunable resonator. In one embodiment, a tunable resonator includes a transmission line comprising at least two inductor segments and a tap between each of the at least two inductor segments. The resonator also includes one less switch than a number of the at least two inductor segments on the transmission line. Each switch is coupled to one of the taps. And, each switch is operable to decouple at least one of the at least two inductor segments in the transmission line by shunting at least a portion of the transmission line to ground to change a resonant frequency of the transmission line.

Abstract: A method for treating a subject having or likely to develop a neurodegenerative disease, wherein the subject is administered a pharmaceutically effective amount of a compound within the generic structure (1) wherein R1 is either —R or —SR, wherein R is a hydrocarbon group containing 1-20 carbon atoms and optionally containing one or more heteroatoms selected from oxygen, nitrogen, and sulfur; and R2 is selected from the group consisting of —OR?, —OPO32?, and —OC(O)R?, wherein R? is a hydrogen atom or a hydrocarbon group containing 1-6 carbon atoms; and wherein Formula (1) may include pharmaceutically acceptable salts, solvates, and polymorphs thereof, and wherein the subject may be identified as positive, before or during treatment, for at least one marker, including, for example, amyloid plaques, neurofibrillary tangles, decline in brain glucose metabolism, decline in thiamine diphosphate-dependent enzyme activity, and increase in advanced glycation end products.

Abstract: Lithium ion batteries, electrodes, nanofibers, and methods for producing same are disclosed herein. Provided herein are batteries having (a) increased energy density; (b) decreased pulverization (structural disruption due to volume expansion during lithiation/de-lithiation processes); and/or (c) increased lifetime. In some embodiments described herein, using high throughput, water-based electrospinning process produces nanofibers of high energy capacity materials (e.g., ceramic) with nanostructures such as discrete crystal domains, mesopores, hollow cores, and the like; and such nanofibers providing reduced pulverization and increased charging rates when they are used in anodic or cathodic materials.

Abstract: Conducting coatings disposed on a metal member. The conducting coatings may have a desired texture and provide homoepitaxial or heteroepitaxial coating of an electrodeposited layer. A conducting coating may be formed by applying a shear force during deposition of the conducting coating. The conducting coatings may be used in anodes of various electrochemical devices. A conducting coating, which may be part of an electrochemical device, may have an electrochemically deposited layer disposed on at least a portion of a surface of the conducting coating. The electrochemically deposited layer may be reversibly electrochemically deposited.

Abstract: A method providing direct access to porous three-dimensionally (3D) continuous polymer network structures and shapes by combining BCP-resol co-assembly with CO2 laser-induced transient heating. The CO2 laser source transiently heats the BCP-directed resol hybrid films to high temperatures at the beam position, inducing locally controlled resol thermopolymerization and BCP decomposition in ambient conditions. This enables shaping of BCP-directed porous resin structures with tunable 3D interconnected pores in a single process. Pore size can be varied from 10 nm to about 600 nm.

Abstract: Provided herein are high throughput continuous or semi-continuous reactors and processes for manufacturing graphenic materials, such as graphene oxide. Such processes are suitable for manufacturing graphenic materials at rates that are up to hundreds of times faster than conventional techniques, have little batch-to-batch variation, have a high degree of tunability, and have excellent performance characteristics.

Abstract: A vertical gallium oxide (Ga2O3) device having a substrate, an n-type Ga2O3 drift layer on the substrate, an, n-type semiconducting channel extending from the n-type Ga2O3 drift layer, the channel being one of fin-shaped or nanowire shaped, an n-type source layer disposed on the channel; the source layer has a higher doping concentration than the channel, a first dielectric layer on the n-type Ga2O3 drift layer and on sidewalls of the n-type semiconducting channel, a conductive gate layer deposited on the first dielectric layer and insulated from the n-type source layer, n-type semiconducting channel as well as n-type Ga2O3 drift layer, a second dielectric layer deposited over the conductive gate layer, covering completely the conductive gate layer on channel sidewalls and an ohmic source contact deposited over the n-type source layer and over at least a part of the second dielectric layer; the source contact being configured not to be in electrical contact with the conductive gate layer.

Abstract: Provided is a method to identify subjects with inflammatory diseases, such as inflammatory bowel disease, for their suitability for treatment with antifungal compounds. The method comprises identification of loss-of-function in the gene CX3CR1.

Abstract: Metal-chelating compositions having the structure (1a) wherein: R1, R2, R3, and R4 are independently selected from the following groups: (i) hydrogen atom, (ii) hydrocarbon groups (R) containing 1-12 carbon atoms; (iii) halogen atoms; (iv) —P(R5) (?O)OH groups; (v) —C(?O)OH groups; (vi) —S(?O)2OH groups; and (vii) —OH groups, wherein R5 is selected from hydrocarbon groups (R) and —OH; R1 and R2 may optionally interconnect to form Ring A fused to the ring on which R1 and R2 are present; R3 and R4 may optionally interconnect to form Ring B fused to the ring on which R3 and R4 are present; wherein Ring A and Ring B are optionally and independently substituted with one or more of groups (ii)-(vii). Methods of using the above-described compositions for chelating metal ions having an atomic number of at least 56 (e.g., Ba or Ra) are also described.

Abstract: A High Electron Mobility Transistor (HEMT) device can include an AlN buffer layer on a substrate and an epi-GaN channel layer on the AlN buffer layer. An AlN barrier layer can be on the Epi-GaN channel layer to provide a channel region in the epi-GaN channel layer. A GaN drain region can be recessed into the epi-GaN channel layer at a first end of the channel region and a GaN source region can be recessed into the epi-GaN channel layer at a second end of the channel region opposite the first end of the channel region. A gate electrode can include a neck portion with a first width that extends a first distance above the AlN barrier layer between the GaN drain region and the GaN source region to a head portion of the gate electrode having a second width that is greater than the first width.

Abstract: The present disclosure provides an electrohydraulic device. The device includes a battery having a vessel containing a flowable electrolyte. The battery may be a flow cell battery, such as, for example, a redox flow cell battery. In a flow cell battery, the flowable electrolyte may a catholyte and/or an anolyte. An actuator is in fluidic communication with the vessel of the battery. The actuator is configured to be actuated using the flowable electrolyte. A cation exchange membrane may separate the vessel into an anolyte side and a catholyte side. The actuator may be in fluidic communication with either side (anolyte side or catholyte side) of the vessel.

Abstract: Provided are methods of increasing a response to a chemotherapeutic agent or an immunotherapeutic agent in a patient in need thereof, and methods of treating cancer in a patient in need thereof, comprising administering to the patient a chemotherapeutic agent or an immunotherapeutic agent and a metastasis inhibiting compound, as described in this disclosure.

Abstract: This disclosure provides a method for determining male fertility status. The method comprises determining GM1 distribution patterns following induced sperm capacitation, identifying the frequency of distribution of various patterns, and determining if the frequency distribution of certain GM1 patterns in response to induced capacitation is altered. Based on the change in the frequency distribution patterns of certain patterns in response to induced capacitation, alone or in combination with other sperm attributes, male fertility status can be identified.

Abstract: Hybrid electrodes for batteries are disclosed having a protective electrochemically active layer on a metal layer. Other hybrid electrodes include a silicon salt on a metal electrode. The protective layer can be formed directly from the reaction between the metal electrode and a metal salt in a pre-treatment solution and/or from a reaction of the metal salt added in an electrolyte so that the protective layer can be formed in situ during battery formation cycles.

Abstract: The invention relates to methods of lubricating biological tissue, such as joints, bone, ocular tissue, nasal tissue, tendons, tendon capsule, and vaginal tissue, by contacting the biological tissue with an effective amount of a block copolymer lubricating composition which functions at least or better than lubricin. In particular embodiments, the method is used to treat osteoarthritis. In specific embodiments, the block copolymer has an ammonium-containing polymer block and a non-ionic hydrophilic polymer block, or the copolymer has a carboxylic acid-containing polymer block and a non-acid non-ionic hydrophilic polymer block.

Abstract: Provided are phenazine copolymers and methods of making and using phenazine copolymers. The phenazine copolymers may be made from one or more phenazine precursors and one or more co-monomer precursors, one or more phenazine precursors and one or more cross-linking precursors, or one or more phenazine precursors and both one or more cross-linking precursors and one or more co-monomer precursors. The phenazine copolymers may be used in/on cathodes. The cathodes may be used in a variety of devices, such as, for example, batteries or supercapacitors.

Abstract: The present disclosure describes a device that can be implanted into the left atrial appendage for occlusion. The device can prevent or reduce thrombus formation in this anatomic region for patients with atrial fibrillation. This device includes a patient-specific inflatable device that represents a patient's anatomy or morphological class. The inflatable device can be designed by imaging (e.g., computed tomography, magnetic resonance imaging) the patient's anatomy. Through a catheter (or surgically), the inflatable device can be filled with an inflation fluid to occlude the appendage in a patient-specific fashion.

Abstract: The present disclosure is directed to genetically modified bacteria that produce a diffusible signal factor (DSF). The disclosure also provides methods for treating or preventing Salmonella infection/invasion in a subject. The disclosure further provides vectors and compositions for carrying out the methods disclosed herein.

Abstract: Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HCN-related disorders (e.g., pain) with the compounds in a subject, by administering the compounds and/or compositions described herein.